For further information and to obtain a copy of the treatment protocols listed below, please fill out the Histiocyte Society Information Request form.

LCH-III
The LCH III study, an international, multicenter, prospective clinical study, opened on April 1, 2001. It is comprised of a randomized clinical trial for multisystem "risk" patients, a randomized clinical trial for multisystem "low-risk" patients, and a pilot study for patients with single-system multifocal bone disease and localized "special sites." Click here for a list of institutions that have implemented the LCH-III clinical trial, following approval by their Institutional Review Boards (IRBs).  

Important Update February 2008
While the LCH-III study remains open for patient follow-up, new patients are not being accepted in North America.  For more information please download the appropriate Progress Report below.

LCH-III Progress Report - North America 

LCH-III Progress Report - All other countries

Scientific Review of LCH-II Manuscript

HLH-2004
The HLH-2004 protocol opened on January 1, 2004, and is designed for patients with inherited, familial hemophagocytic lymphohistiocytosis (FHLH) and nonfamilial hemophagocytic lymphohistiocytosis (HLH). This protocol is based on the HLH-94 protocol with minor therapeutic modifications.  

LCH-Adult-I
The LCH-A-I clinical trial opened on October 1, 2004.  Goals are to define and implement a uniform initial evaluation and stratification of adults with single-system disease, CNS lesions, isolated pulmonary disease, and multisystem LCH.


LCH-CNS-2003
This registry was created in June 2003 to collect information on applied therapeutic strategies for future coordinated treatment approaches. No specific treatment recommendations are provided.  Please note that this is a registry and provides diagnostic guidelines for Central Nervous System Disease in LCH.


LCH-S-2005
This clinical trial was created in December 2005 and is now open for enrollment.  It is an international phase II study evaluating the combination of Cladribine (2-CdA) and Cytarabine Cytosine-arabinoside (Ara-C) in LCH patients who fail to respond to front-line chemotherapy AND who have risk organ involvement.


LCH-HCT
This clinical trial was designed in 2006 with the primary objective of determining the overall and disease free survival at 1 and 3 years after reduced intensity hematopoietic cell transplantation (RI-HCT) in poor risk patients with Langerhans Cell Histiocytosis.